Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its news flow is heavily centered on TSHA-102, a self-complementary, intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
On this TSHA news page, readers can follow company announcements about clinical progress in the REVEAL Phase 1/2 and pivotal trials, as well as the ASPIRE safety-focused study in younger females with Rett syndrome. Taysha regularly reports on enrollment status, dosing milestones, interim and longer-term safety and efficacy data, and supplemental analyses of functional outcomes and developmental milestones achieved post-TSHA-102.
Investors and followers of TSHA stock will also find regulatory updates, such as the FDA’s Breakthrough Therapy designation for TSHA-102 and alignment on pivotal trial protocols and statistical analysis plans intended to support a future Biologics License Application. Additional news items include financial results, capital-raising activities, amendments to at-the-market equity programs, and inducement grants of stock options under the company’s inducement plan.
Because Rett syndrome is a rare neurodevelopmental disorder with no approved disease-modifying therapies that address its genetic root cause, developments from Taysha’s TSHA-102 program are closely watched by patients, caregivers and market participants. This page aggregates these company-issued updates so that readers can monitor how clinical data, regulatory interactions and corporate actions may shape the trajectory of TSHA-102 and the broader Taysha pipeline over time.
Taysha Gene Therapies (Nasdaq: TSHA) announced that on May 1, 2026 the Compensation Committee granted restricted stock units totaling 188,000 shares to five new employees under the 2023 Inducement Plan as an inducement under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date and are subject to each employee's continued service through each vesting date.
Taysha Gene Therapies (Nasdaq: TSHA) will release first quarter 2026 financial results for the period ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026 at 8:30 AM ET. Participants can access the live webcast via the company’s Events and Presentations page at ir.tayshagtx.com, and an archived replay will be available afterward.
Taysha Gene Therapies (Nasdaq: TSHA) will present preclinical in vitro data at ASGCT 2026 showing scAAV9 drives ~30-fold higher MeCP2 protein expression versus single-stranded AAV9 and that miniMeCP2 is functionally comparable to full-length MeCP2 in neuronal cells. The data support TSHA-102 construct design and lumbar intrathecal CNS delivery; poster: May 14, 2026, Poster 3481.
Taysha Gene Therapies (Nasdaq: TSHA) granted inducement equity to four new employees on April 1, 2026.
The Compensation Committee awarded 300,000 RSUs (vest in four equal annual installments) and an option for 92,400 shares with a $4.31 exercise price, a 10-year term, and four-year vesting.
Taysha Gene Therapies (Nasdaq: TSHA) reported full‑year 2025 results and a corporate update on March 19, 2026. Key program milestones include multiple patients dosed in the REVEAL pivotal trial, FDA clearance to initiate the ASPIRE trial, written FDA alignment on CMC/PPQ comparability, and no treatment‑related SAEs or DLTs as of March 2026.
Financials: R&D $86.4M, G&A $33.9M, net loss $109.0M, and $319.8M cash, with runway expected into 2028.
Taysha Gene Therapies (Nasdaq: TSHA) will report full-year 2025 financial results and host a corporate update conference call and webcast on Thursday, March 19, 2026 at 8:30 AM ET.
Investors can access the live webcast and later archived replay via the company’s Events and Presentations page at ir.tayshagtx.com for the company update and Q&A.
Taysha Gene Therapies (Nasdaq: TSHA) announced on March 2, 2026 that its Compensation Committee granted inducement awards under the 2023 Inducement Plan for two new employees.
The awards: 156,870 RSUs vesting in four equal annual installments, and a stock option to purchase 134,460 shares at an exercise price of $4.53 (10-year term) with four-year vesting.
Grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and vesting is subject to continued service.
Taysha Gene Therapies (Nasdaq: TSHA) granted inducement restricted stock units totaling 349,000 shares to three new employees on February 2, 2026, under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the first anniversary of the vesting commencement date, subject to continued service through each vesting date.
Taysha Gene Therapies (Nasdaq: TSHA) reported progress on its TSHA-102 pivotal program for Rett syndrome, including dosing the first REVEAL pivotal trial patient in Q4 2025 and ongoing enrollment across multiple sites. The REVEAL pivotal trial is a single-arm, open-label study of a single intrathecal dose of 1x1015 vg in 15 females aged 6 to <22 years with a six-month interim analysis that may support a BLA.
The company said it reached written FDA alignment to include at least three months of safety data from the ASPIRE trial (N=3, aged 2 to <4 years) in a planned BLA to enable a broad label for patients ≥2 years. Dosing completion for REVEAL and ASPIRE is expected in Q2 2026, with a REVEAL Part A update expected in H1 2026.
Taysha Gene Therapies (Nasdaq: TSHA) announced that on December 3, 2025 its Compensation Committee granted inducement stock options to two new employees totaling 212,000 shares under the 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $4.49 (the closing price on the grant date), a 10-year term, and a four-year vesting schedule: 25% vest on the first anniversary of the vesting commencement date and the remaining 75% vest monthly over the next 36 months, subject to continued service.